



# The mind-body interface

FORUM Annual Lecture 2017

Keynote by Professor Kevin Tracey

President and CEO, The US Feinstein Institute for Medical Research

*Followed by a panel discussion*

6 September 2017

British Academy



We will be filming and livestreaming the lecture, and taking photographs. If you do not wish to have your photograph used, please make yourself known to an Academy staff member at the start of the meeting. Academy staff can be identified by their lanyards. We will be live tweeting from @acmedsci using #FORUM2017, so please feel free to tweet about the event.

# FORUM

## Linking life science sectors

*“The Academy’s FORUM provides an independent platform where stakeholders from across the life sciences sector can connect and take forward national discussions on scientific opportunities and technology trends”*

Professor Sir John Bell GBE FRS HonFREng FMedSci, Regius Professor of Medicine, University of Oxford

**The Academy's FORUM was established to catalyse connections across industry, academia and the wider healthcare sector.**

**Through the FORUM we aim to promote:**

- **Sustainable translation of research outputs into health and wealth gains.**
- **A vibrant innovation ecosystem.**
- **A strong UK industry.**

The success of the FORUM relies on supporter organisations who make an annual donation. These donations enable the Academy to deliver its FORUM programme of high profile meetings, including the Annual Lecture.

To discuss how your organisation can join the network of FORUM supporters, please contact [forum@acmedsci.ac.uk](mailto:forum@acmedsci.ac.uk).



@acmedsci  
#FORUM2017

# Programme

14.30 – 15.00	<b>Registration and refreshments</b>
15.00 – 15.10	<b>Welcome and introduction</b> Professor Sir Robert Lechler PMedSci (chair), President, Academy of Medical Sciences
15.10 – 16.00	<b>Keynote - Molecular mechanisms in bioelectronic medicine</b> Professor Kevin Tracey, President and Chief Executive Officer, The Feinstein Institute for Medical Research, New York
16.00 – 17.15	<b>Panel discussion: Integration across the mind-body interface</b> Chaired by Professor Sir Robert Lechler PMedSci, President, Academy of Medical Sciences <ul style="list-style-type: none"><li>• Professor Ed Bullmore FMedSci, Vice President of ImmunoPsychiatry, GlaxoSmithKline, and Head of Department of Psychiatry, University of Cambridge</li><li>• Professor Matthew Hotopf FMedSci, Professor of General Hospital Psychiatry, King's College London</li><li>• Professor Brenda Penninx, Professor of Psychiatric Epidemiology, EMGO Institute for Health and Care Research, VU University Medical Center Amsterdam</li><li>• Melissa Smith, Ophthalmology nurse and service user, East Sussex Healthcare NHS Trust</li><li>• Professor Kevin Tracey, President and Chief Executive Officer, The Feinstein Institute for Medical Research, New York</li></ul>
17.15 – 17.20	<b>Closing comments from the President</b> Professor Sir Robert Lechler PMedSci, President, Academy of Medical Sciences
17.20 – 18.30	<b>Drinks reception</b>





## Professor Sir Robert Lechler PMedSci

*President, Academy of Medical Sciences*

Sir Robert is currently Provost and Senior Vice-President (Health) at King's College London, and Executive Director of King's Health Partners. He is a strong advocate of the Academic Health Science Centre model of university-healthcare partnerships.

His clinical and research career have been focused on the pursuit of clinical transplantation tolerance. He worked in *in vitro* and *in vivo* rodent models. More recently he has helped to define biomarkers of clinical tolerance and is now helping to lead first in man trials of cell therapy to promote immune tolerance in recipients of kidney and liver organ transplants. Sir Robert has published over 200 papers in this field, led an EU consortium, and was awarded the Novartis Established Investigator Award by the American Transplant Society. In addition, Robert is a founding member of MedCity which fosters the South East England life sciences cluster, has served on the Mayor of London's Health Board and was a Trustee and member of Council of the British Heart Foundation from 2010 – 2016.



## Professor Kevin Tracey

*President and CEO, The Feinstein Institute for Medical Research, New York*

Kevin Tracey, MD, is President and CEO of the Feinstein Institute for Medical Research; Executive VP for Research at Northwell Health; Professor of Molecular Medicine and Neurosurgery and Associate Dean, Research, at Hofstra Northwell School of Medicine.

A global leader in the study of the molecular basis of inflammation, Professor Tracey has pioneered breakthrough discoveries for thirty years. These include the identification of the therapeutic potential for monoclonal antibodies against TNF, which enabled development of a new class of biological therapies currently marketed at more than \$30B annually. His laboratory discovered the neural mechanism for controlling the immunological responses to infection and injury, and developed devices to replace anti-inflammatory drugs in successful clinical trials of rheumatoid arthritis - 'bioelectronic medicines'.

An inventor with more than 60 US patents, his biotechnology experience includes co-founding three companies. He is also co-founder and Councillor of the Global Sepsis Alliance, a non-profit organisation supporting the efforts of more than 1 million caregivers to understand and combat sepsis, a major cause of death worldwide. In addition, he serves as a member of the Board of Directors of the New York Genome Center, and is Editor-in-Chief of Bioelectronic Medicine, Advisory Editor of The Journal of Experimental Medicine, and Editor Emeritus of Molecular Medicine.



## Professor Ed Bullmore FMedSci

*Vice President of ImmunoPsychiatry, GlaxoSmithKline, and Head of Department of Psychiatry, University of Cambridge*

Professor Ed Bullmore FMedSci trained in medicine at the University of Oxford and St Bartholomew's Hospital, London; then in psychiatry at the Bethlem Royal & Maudsley Hospital, London. He moved to Cambridge as Professor of Psychiatry in 1999 and is currently Co-Chair of Cambridge Neuroscience, Scientific Director of the Wolfson Brain Imaging Centre, and Head of the Department of Psychiatry, in the University.

He is also an honorary Consultant Psychiatrist and Director of R&D in Cambridgeshire & Peterborough Foundation NHS Trust; and, since 2005, he has worked half-time for GlaxoSmithKline, currently focusing on immuno-psychiatry. He has published more than 500 scientific papers and, in 2016, he was listed by Thomson Reuters as one of the most highly cited scientists worldwide in 'Neuroscience & Behaviour' and in 'Psychology & Psychiatry'.



## Professor Matthew Hotopf FMedSci

*Professor of General Hospital Psychiatry, King's College London*

Matthew Hotopf is a psychiatrist and researcher. He is Director of the South London and Maudsley NHS Foundation Trust National Institute of Health Research Biomedical Research Centre (BRC) and Professor of General Hospital Psychiatry at the Institute of Psychiatry, Psychology and Neuroscience, King's College London. Matthew trained in epidemiology at the London School of Hygiene and Tropical Medicine and in Psychiatry at the Maudsley. His main area of research is in the grey area between medicine and psychiatry, exploring the interface between mental and physical health, and his research uses 'big data' approaches to understand this interface better.

He has worked extensively in areas where mental health relates to other walks of life – including occupational and military health, mental health law, and the wider community. He has received many research grants, including the Innovative Medicines Initiative RADAR-CNS (Remote Assessment of Disease And Relapse in CNS disorders) program, which seeks to use data streams from smartphones and wearables to assess and predict health states in people with epilepsy, multiple sclerosis and depression. He works clinically as a liaison psychiatrist at King's College Hospital and St Christopher's Hospice, and leads the award winning IMPARTS (Integrating mental and physical health, Research training and Service) project which looks to provide better mental healthcare to people with physical illnesses. He received the Academy of Psychosomatic Medicine's 2016 Wayne Katon Research Award, is an NIHR Senior Investigator and Fellow of the Academy of Medical Sciences.





## Professor Brenda Penninx

*Professor of Psychiatric Epidemiology, EMGO Institute for Health and Care Research, VU University Medical Center Amsterdam*

Professor Brenda Penninx is Professor at the Department of Psychiatry of the VU University Medical Center in Amsterdam. She is program leader at both the Amsterdam Public Health and Amsterdam Neuroscience Research Institutes.

Since 2004, she leads as principal investigator of the multi-site Netherlands Study of Depression and Anxiety (NESDA), a longitudinal study of the course and consequences of depressive and anxiety disorders. In addition, Prof Penninx has been involved in several Dutch and international longitudinal mental health cohort and intervention studies for the last 15 years.

Her research encompasses three themes. First, the examination of the role of psychosocial, neurobiological and genetic factors in the aetiology and course of depressive and anxiety disorders. Second, the understanding of treatment response variability from biological and psychosocial perspectives and applying that understanding to the development and testing of new ways to manage depression. Third, the examination of underlying mechanisms explaining the bidirectional interaction between mental and somatic health.

Professor Penninx has mentored more than 30 researchers in obtaining their PhD, and currently supervises 4 Assistant Professors, 6 Post-doc fellows, and 23 PhD students. She has over 750 peer-reviewed publications and belongs to the highest 1% most cited researchers according to Thomas Reuters. In 2016, she was elected as member of the Royal Dutch Academy of Sciences and Arts.



## Melissa Smith

*Ophthalmology nurse and service user, East Sussex Healthcare NHS Trust*

Melissa Smith qualified as an adult nurse in 1993. Since then, she has worked for several NHS Trusts, mainly in the fields of Elderly Care and Adult Intensive Care. Melissa currently works as an Ophthalmology Nurse.

Melissa is a service user participating in the BIOmarkers in DEPRESSION (BIODEP) research study that aims to characterise the role of inflammatory processes in depression, including the identification of a subset of patients that is most likely to respond more effectively to an anti-inflammatory drug than to conventional anti-depressants. This has involved participating in questionnaires, giving blood samples and magnetic resonance imaging (MRI) and positron emission topography (PET) scans in Cambridge.

# FORUM programme 2017

1 February	<b>Geographical clusters follow-up</b> A follow up to the 2015 workshop, held jointly with the Wellcome Trust.
20 March	<b>A stratified approach to respiratory disease</b> A joint roundtable with NHS England to explore stratification of respiratory disease, specifically severe asthma, in the NHS. This was held as part of a series of meetings exploring adoption of stratified medicine in the NHS.
13 June	<b>Accelerating access to medical innovation: a research agenda for innovation science</b> Supported by CASMI, MRC and NIHR, this workshop explored a research agenda for accelerating development and uptake of medical innovation.
3 July	<b>Looking to the future: oncology endpoints in clinical research</b> A workshop with the ABPI exploring the relevance, utility and acceptability of traditional and 'new' oncology endpoints across different stakeholder perspectives.
21 July	<b>Digital maturity of health and social care systems: the industry perspective</b> Held in partnership with Oxford AHSN, this roundtable focused on the industry perspective of digital maturity in the UK healthcare system.
6 September	<b>Personalised psychiatry</b> A roundtable to discuss current and future opportunities for a stratified, or 'personalised', approach to psychiatry.
6 September	<b>2017 FORUM Annual Lecture: The mind-body interface</b> Professor Kevin Tracey, President and CEO of the Feinstein Institute for Medical Research, will give a keynote lecture followed by a panel session with distinguished guests from across the life sciences sector.
Winter 2017	<b>Early detection and diagnosis research</b> A joint workshop with Cancer Research UK exploring advances in early detection and diagnosis research, the implications and opportunities of these developments, and the challenges in this field and ways forward.
Winter 2017	<b>Bridging the preclinical-clinical boundary</b> A workshop exploring ways to better integrate across earlier stage discovery research and clinical research and practice, in partnership with the ABPI.



@acmedsci  
#FORUM2017

Wi-Fi: 10-11 cht  
Password: hospitality



Academy of Medical Sciences  
41 Portland Place  
London W1B 1QH

+44 (0) 20 3141 3200  
[FORUM@acmedsci.ac.uk](mailto:FORUM@acmedsci.ac.uk)

Registered Charity no. 1070618  
Registered Company no. 3520281